

# Holger Nef

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3747340/publications.pdf>

Version: 2024-02-01

70  
papers

2,644  
citations

331538

21  
h-index

189801

50  
g-index

73  
all docs

73  
docs citations

73  
times ranked

3264  
citing authors

#	ARTICLE	IF	CITATIONS
1	Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. <i>EuroIntervention</i> , 2015, 10, 1144-1153.	1.4	411
2	Diagnostic Accuracy of Fast Computational Approaches to Derive Fractional Flow Reserve From Diagnostic Coronary Angiography. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 2024-2035.	1.1	394
3	Diagnostic Performance of In-Procedure Angiography-Derived Quantitative Flow Reserve Compared to Pressure-Derived Fractional Flow Reserve: The FAVOR II Europe-Japan Study. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	240
4	Safety and Effectiveness of Coronary Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Stenoses. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008434.	1.4	234
5	Contemporary practice and technical aspects in coronary intervention with bioresorbable scaffolds: a European perspective. <i>EuroIntervention</i> , 2015, 11, 45-52.	1.4	131
6	Coronary Computed Tomographic Prediction Rule for Time-Efficient Guidewire Crossing Through Chronic Total Occlusion. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 257-267.	1.1	129
7	Mechanisms of Very Late Bioresorbable Scaffold Thrombosis. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2330-2344.	1.2	117
8	Incidence and outcome of peri-procedural transcatheter heart valve embolization and migration: the TRAVEL registry (Transcatheter Heart Valve Embolization and Migration). <i>European Heart Journal</i> , 2019, 40, 3156-3165.	1.0	92
9	Pacemaker implantation after TAVI: predictors of AV block persistence. <i>Clinical Research in Cardiology</i> , 2018, 107, 60-69.	1.5	71
10	Outcome after transvascular transcatheter aortic valve implantation in 2016. <i>European Heart Journal</i> , 2018, 39, 667-675.	1.0	61
11	Trends in aortic valve replacement in Germany in 2015: transcatheter versus isolated surgical aortic valve repair. <i>Clinical Research in Cardiology</i> , 2017, 106, 411-419.	1.5	52
12	Release Kinetics of Inflammatory Biomarkers in a Clinical Model of Acute Myocardial Infarction. <i>Circulation Research</i> , 2015, 116, 867-875.	2.0	51
13	Short-term outcome of patients with ST-segment elevation myocardial infarction (STEMI) treated with an everolimus-eluting bioresorbable vascular scaffold. <i>Clinical Research in Cardiology</i> , 2014, 103, 141-148.	1.5	49
14	Detection of Myocardial Injury by CMR After Transcatheter Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2014, 64, 349-357.	1.2	46
15	Mapping interventional cardiology in Europe: the European Association of Percutaneous Cardiovascular Interventions (EAPCI) Atlas Project. <i>European Heart Journal</i> , 2020, 41, 2579-2588.	1.0	44
16	Plasma microRNA-21 for the early prediction of acute kidney injury in patients undergoing major cardiac surgery. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 760-766.	0.4	36
17	Non-Invasive Approach for Evaluation of Pulmonary Hypertension Using Extracellular Vesicle-Associated Small Non-Coding RNA. <i>Biomolecules</i> , 2019, 9, 666.	1.8	30
18	Bioresorbable vascular scaffold use for coronary bifurcation lesions: A substudy from GHOST EU registry. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 47-56.	0.7	28

#	ARTICLE	IF	CITATIONS
19	Evaluation of the short- and long-term safety and therapy outcomes of the everolimus-eluting bioresorbable vascular scaffold system in patients with coronary artery stenosis: Rationale and design of the Germanâ€‘Austrian ABSORB RegIstRy (GABI-R). <i>Cardiovascular Revascularization Medicine</i> , 2016, 17, 34-37.	0.3	24
20	1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 440-449.	1.1	23
21	Neuropeptide Y as an indicator of successful alterations in sympathetic nervous activity after renal sympathetic denervation. <i>Clinical Research in Cardiology</i> , 2015, 104, 1064-1071.	1.5	21
22	Renal denervation in hypertensive patients not on blood pressure lowering drugs. <i>Clinical Research in Cardiology</i> , 2016, 105, 755-762.	1.5	21
23	A multicenter postâ€‘marketing evaluation of the Elixir DESolve <sup>®</sup> Novolimusâ€‘eluting bioresorbable coronary scaffold system: First results from the DESolve PMCF study. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, 1021-1027.	0.7	21
24	Feasibility of Coronary Access in Patients With Acute Coronary Syndrome and Previous TAVR. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1578-1590.	1.1	18
25	Direct admission versus transfer of AMI patients for primary PCI. <i>Clinical Research in Cardiology</i> , 2011, 100, 217-225.	1.5	16
26	Bioresorbable Everolimus-Eluting Vascular Scaffold for Long Coronary Lesions. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 560-568.	1.1	16
27	Influence of Renal Sympathetic Denervation on Cardiac Extracellular Matrix Turnover and Cardiac Fibrosis. <i>American Journal of Hypertension</i> , 2015, 28, 1285-1292.	1.0	15
28	Impact of overlapping on 1â€‘year clinical outcomes in patients undergoing everolimusâ€‘eluting bioresorbable scaffolds implantation in routine clinical practice: Insights from the European multicenter GHOSTâ€‘EU registry. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 812-818.	0.7	15
29	Relative risk of plaque erosion among different age and sex groups in patients with acute coronary syndrome. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 352-359.	1.0	15
30	CILP1 as a biomarker for right ventricular maladaptation in pulmonary hypertension. <i>European Respiratory Journal</i> , 2021, 57, 1901192.	3.1	15
31	Sham Surgery and Inter-Individual Heterogeneity Are Major Determinants of Monocyte Subset Kinetics in a Mouse Model of Myocardial Infarction. <i>PLoS ONE</i> , 2014, 9, e98456.	1.1	15
32	Aortic annulus eccentricity before and after transcatheter aortic valve implantation: Comparison of balloon-expandable and self-expanding prostheses. <i>European Journal of Radiology</i> , 2015, 84, 1242-1248.	1.2	13
33	Release kinetics of N-terminal pro-B-type natriuretic peptide in a clinical model of acute myocardial infarction. <i>Clinica Chimica Acta</i> , 2014, 429, 34-37.	0.5	12
34	Comparison of standard- and high-dose intracoronary adenosine for the measurement of coronary fractional flow reserve (FFR). <i>Clinical Research in Cardiology</i> , 2016, 105, 1003-1010.	1.5	12
35	Challenges of recognizing bicuspid aortic valve in elderly patients undergoing TAVR. <i>International Journal of Cardiovascular Imaging</i> , 2020, 36, 251-256.	0.7	12
36	Aortic valve replacement in Germany in 2019. <i>Clinical Research in Cardiology</i> , 2021, 110, 460-465.	1.5	12

#	ARTICLE	IF	CITATIONS
37	Specific biomarkers of myocardial inflammation and remodeling processes as predictors of mortality in high-risk patients undergoing percutaneous mitral valve repair (MitraClip). <i>Clinical Cardiology</i> , 2018, 41, 481-487.	0.7	11
38	SPARCL1 as a biomarker of maladaptive right ventricular remodeling in pulmonary hypertension. <i>Biomarkers</i> , 2020, 25, 290-295.	0.9	11
39	Lower mortality in an all-comers aortic stenosis population treated with TAVI in comparison to SAVR. <i>Clinical Research in Cardiology</i> , 2020, 109, 611-615.	1.5	10
40	Clinical outcomes of patients with diabetes mellitus treated with Absorb bioresorbable vascular scaffolds: a subanalysis of the <sc>E</sc>uropean <sc>M</sc>ulticentre <sc>GHOST</sc>â€<sc>EU</sc><sc>R</sc>egistry. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 444-453.	0.7	8
41	Who Is Afraid of CRP? Elevated Preoperative CRP Levels Might Attenuate the Increase in Inflammatory Parameters in Response to Lung Cancer Surgery. <i>Journal of Clinical Medicine</i> , 2020, 9, 3340.	1.0	7
42	Analysis of Atrial Fibrillation Treatment Regimes in a Multicenter Cohort of Transcatheter Edge-to-Edge Mitral Valve Repair Patients. <i>Journal of Interventional Cardiology</i> , 2020, 2020, 1-7.	0.5	7
43	Initial experience with a novel, modular, minimalistic approach for transfemoral aortic valve implantation. <i>International Journal of Cardiology</i> , 2021, 332, 54-59.	0.8	7
44	Galectin-3 and ST2 as predictors of therapeutic success in high-risk patients undergoing percutaneous mitral valve repair (MitraClip). <i>Clinical Cardiology</i> , 2018, 41, 1164-1169.	0.7	6
45	Randomized Comparison of Optical Coherence Tomography Versus Angiography to Guide Bioresorbable Vascular Scaffold Implantation: The OPTICO BVS Study. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 1244-1250.	0.3	6
46	Myeloid-related protein 8/14 and high-sensitivity cardiac troponin I to differentiate type 2 myocardial infarction. <i>International Journal of Cardiology</i> , 2020, 304, 144-147.	0.8	6
47	Osteopontin and galectin-3 as biomarkers of maladaptive right ventricular remodeling in pulmonary hypertension. <i>Biomarkers in Medicine</i> , 2021, 15, 1021-1034.	0.6	6
48	Biomarker response and therapy prediction in renal denervation therapy – the role of MR-proadrenomedullin in a multicenter approach. <i>Biomarkers</i> , 2017, 22, 225-231.	0.9	5
49	Anatomical suitability and off-label use of contemporary transcatheter heart valves. <i>International Journal of Cardiology</i> , 2022, 350, 96-103.	0.8	5
50	Evaluation of cystatin C and neutrophil gelatinase-associated lipocalin as predictors of mortality in patients undergoing percutaneous mitral valve repair (MitraClip). <i>Clinical Cardiology</i> , 2018, 41, 1474-1479.	0.7	4
51	Long-term follow-up and predictors of target lesion failure after implantation of everolimus-eluting bioresorbable scaffolds in real-world practice. <i>International Journal of Cardiology</i> , 2020, 312, 42-47.	0.8	4
52	Restenosis patterns after bioresorbable vascular scaffold implantation: Angiographic substudy of the <sc>GHOST</sc>â€<sc>EU</sc> registry. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, 276-282.	0.7	4
53	Application and Validation of the Tricuspid Annular Plane Systolic Excursion/Systolic Pulmonary Artery Pressure Ratio in Patients with Ischemic and Non-Ischemic Cardiomyopathy. <i>Diagnostics</i> , 2021, 11, 2188.	1.3	4
54	Percutaneous closure of a hemodynamically significant connection between the inferior vena cava and the left atrium. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 86, 773-776.	0.7	3

#	ARTICLE	IF	CITATIONS
55	Impact of Rhythm vs. Rate Control in Atrial Fibrillation on the Long-Term Outcome of Patients Undergoing Transcatheter Edge-to-Edge Mitral Valve Repair. <i>Journal of Clinical Medicine</i> , 2021, 10, 5044.	1.0	3
56	Micro-dislodgement of a self-expanding transcatheter heart valve: Incidence, predictors, and outcomes. <i>International Journal of Cardiology</i> , 2022, 358, 77-82.	0.8	3
57	First Experience with the New MitraClip NTR/XTR Device. <i>Structural Heart</i> , 2019, 3, 288-295.	0.2	2
58	Single versus double use of a suture-based closure device for transfemoral aortic valve implantation. <i>International Journal of Cardiology</i> , 2021, 331, 183-188.	0.8	2
59	Latest Developments in Robotic Percutaneous Coronary Intervention. <i>Surgical Technology International</i> , 0, , .	0.1	2
60	Coronary Artery Aneurysm With Thrombosis After Implantation of a Bioresorbable Coronary Artery Scaffold. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, e173-e174.	1.1	1
61	No evidence for humoral autoimmunity against cardiomyocytes, adrenergic or muscarinic receptors in patients with Tako-Tsubo cardiomyopathy. <i>Immunobiology</i> , 2019, 224, 220-222.	0.8	1
62	Comparison between treatment of "established" versus complex "off-label" coronary lesions with Absorb <sup>®</sup> bioresorbable scaffold implantation: results from the GABI-R <sup>®</sup> registry. <i>Clinical Research in Cardiology</i> , 2020, 109, 374-384.	1.5	1
63	Clinical presentation does not affect acute mechanical performance of the Novolimus-eluting bioresorbable vascular scaffold as assessed by optical coherence tomography. <i>Postepy W Kardiologii Interwencyjnej</i> , 2021, 17, 272-280.	0.1	1
64	First-in-Man Coronary Sinus Lead Stabilization Using a Bioresorbable Vascular Scaffold System. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2015, 8, 1518-1519.	2.1	0
65	A true bifurcational stenosis treated with a bioresorbable vascular scaffold and a drug-eluting metallic stent: Degradable meets durable. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, 1184-1188.	0.7	0
66	Response to Letter Regarding Article, "Revisiting the Role of sCD40L as an Inflammatory Biomarker in a Clinical Model of Acute Myocardial Infarction". <i>Circulation Research</i> , 2015, 116, e27.	2.0	0
67	Applicability and procedural success rate of bioresorbable vascular scaffolds for percutaneous coronary intervention in an all-comer cohort of 383 consecutive patients. <i>Acta Cardiologica</i> , 2017, 72, 425-432.	0.3	0
68	Fractional flow reserve and frequency of PCI in patients with coronary artery disease. <i>Herz</i> , 2020, 45, 752-758.	0.4	0
69	Cerebral Tissue Oxygen Saturation Is Enhanced in Patients following Transcatheter Aortic Valve Implantation: A Retrospective Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 1930.	1.0	0
70	Latest Advances in Transcatheter Aortic Valve Implantation (2022).. <i>Surgical Technology International</i> , 2022, 40, .	0.1	0